Every claim, every source.

This 2024 Nature Cell Biology paper from the Madeo lab identified spermidine — a polyamine found in many foods (wheat germ, soybeans, mushrooms, aged cheeses) and produced endogenously — as the essential mediator of fasting-induced autophagy. The authors ran experiments across multiple model systems: yeast, nematodes, mouse cells, and human cell lines (U2OS osteosarcoma cells and H4 neuroglioma cells). Across all systems, blocking spermidine synthesis with the inhibitor DFMO suppressed fasting-induced autophagy — and supplementing exogenous spermidine (100 µM) rescued the autophagy response. The paper also reports human-cohort metabolomics: across multiple cohorts of fasting participants (61 to 109 volunteers per cohort, fasting durations 3 to 16 days), serum spermidine levels rose during fasting. Human PBMCs showed increased hypusination of eIF5A — a downstream effect linking spermidine to translation control and autophagy machinery. The paper's mechanistic claim is significant: spermidine is not just correlated with fasting-induced autophagy; it is required for the response to occur.

This review compares the cardiovascular benefits of eating whole sardines against taking isolated fish-oil supplements. The authors argue that whole sardines provide a "matrix" of nutrients that fish-oil capsules lack: not just EPA and DHA, but calcium, vitamin D, B12, selenium, high-quality protein, and minor compounds (taurine, coenzyme Q10) absent from purified oils. Per 100 grams of cooked sardines, the USDA database reports 24.6 g of protein, 11.5 g of total fat, 473 mg of EPA, 509 mg of DHA, 382 mg of calcium, 4.8 µg of vitamin D, 8.9 µg of B12, and 52.7 µg of selenium. The review surveys randomized trials of sardine consumption versus control diets and concludes that whole-sardine intake produces favourable changes in lipid profile, inflammation markers, and insulin sensitivity, with the additional minerals and protein doing work that omega-3 supplements alone cannot. The framing throughout is that sardines outperform fish-oil supplementation as a delivery vehicle for cardiovascular benefit.

This study used data from the Canadian Study of Adolescent Health Behaviors — a national survey of 2,762 adolescents and young adults — to ask how common intermittent fasting is and whether it correlates with eating-disorder behaviors. The engagement numbers were striking: roughly 48 percent of women, 38 percent of men, and 52 percent of transgender or gender-non-conforming respondents reported practicing some form of intermittent fasting in the past 12 months. The researchers used the Eating Disorder Examination Questionnaire alongside modified Poisson regression to measure associations. Across all three gender groups, intermittent fasting in the past 12 months and the past 30 days was significantly associated with elevated eating-disorder psychopathology — disordered cognitions, restrictive behaviors, and binge-purge cycles. The pattern was strongest and most consistent in women. The authors do not claim fasting causes eating disorders; the data are cross-sectional and cannot prove direction. They argue clinicians screening young patients should treat self-reported intermittent fasting as a meaningful flag.

This Cleveland Clinic-affiliated study followed 1,403 patients who were eligible for a protein-sparing modified fast program over 5 years to answer the question the original 1970s PSMF literature could not: does the dramatic short-term weight loss persist? Of those eligible, 879 (63 percent) actually initiated PSMF; the remaining 524 (37 percent) pursued other dietary approaches and served as a comparison cohort. The 1-year outcomes were dramatic and favored PSMF: -7.6 percent body weight in the PSMF arm versus -1.8 percent in the comparison arm, a 5.8-percentage-point difference (p less than 0.01). At 3 years, PSMF still showed an advantage but smaller: -2.3 percent vs -0.9 percent, a 1.4-point difference. By 5 years, the difference had effectively disappeared: -1.4 percent vs -1.0 percent (p=0.64, not statistically significant). The proportion achieving clinically meaningful (≥5 percent) weight loss told the same story: PSMF was strongly favored at 1 and 3 years, equivalent at 5 years. The honest conclusion: PSMF produces substantial short-term weight loss with good durability through year 3, but by year 5 the advantage over conventional dietary care is gone.

This NEJM review summarizes evidence that intermittent fasting regimens — alternate-day fasting, time-restricted eating, and periodic multi-day fasts — engage a "metabolic switch" from glucose-derived energy to fat- and ketone-derived energy after hepatic glycogen is depleted, typically within 12–36 hours of fasting depending on the individual and the protocol. The authors argue that repeated exposure to this switch produces adaptive responses across organ systems, including improved insulin sensitivity, reduced inflammation, increased mitochondrial biogenesis, enhanced autophagy, and improved stress resistance in cells. The review compiles findings from animal models alongside the available human trials at the time of publication. The review notes that, despite preclinical signals being strong and consistent, the human evidence base is more heterogeneous: the largest gains in metabolic markers (fasting insulin, HOMA-IR, lipid profile, inflammatory markers) appear in adults with obesity or metabolic syndrome, while effects in lean, metabolically healthy individuals are smaller. The authors flag practical issues — adherence over months, the early-fast hunger and irritability phase, and the lack of long-term outcome data — as the main barriers to clinical adoption rather than safety in healthy adults.

This 2019 meta-analysis pooled 26 double-blind randomized placebo-controlled trials of omega-3 PUFA supplementation for depression to ask a specific question: does the EPA-to-DHA ratio matter? The authors found that it does, decisively. Formulations that were either pure EPA or majority EPA (60 percent or more EPA) showed clinical benefit for depressive symptoms at relatively low doses (1 gram per day or less), while pure DHA and DHA-majority formulations did not. The therapeutic effect was specific to EPA-dominant supplementation. The mechanism inference is that EPA's anti-inflammatory effects (via resolvins and reduction of pro-inflammatory eicosanoids) drive the antidepressant signal, while DHA's role in neuronal membrane structure does not similarly translate to mood benefit at supplementation doses. The paper is the most-cited recent meta-analysis on omega-3 and depression and has shaped subsequent dosing recommendations: when omega-3 is used adjunctively for depressive disorders, EPA-dominant formulations at sub-gram doses are the evidence-supported choice. The paper does not claim omega-3 replaces antidepressant medication; it supports adjunctive use.

This Nature Reviews Neuroscience paper from Mark Mattson — the most cited researcher on fasting and brain health — synthesizes the case that periodic shifts between fed and fasted metabolic states are essential for optimal brain function. Mattson coined the term "intermittent metabolic switching" (IMS) for the pattern: eating depletes liver glycogen, fasting forces ketone production, and the cycle repeats. The review argues this oscillation is what humans evolved with, and that modern continuous-feeding patterns disrupt it with cognitive and neurological consequences. The mechanistic story focuses on β-hydroxybutyrate (BHB), which is transported into neuronal mitochondria as fuel but also acts as a signaling molecule. BHB induces brain-derived neurotrophic factor (BDNF), which promotes synaptic plasticity, neurogenesis in the hippocampus, and resistance to neuronal injury. Mattson reviews evidence connecting IMS to improved cognition, mood regulation, motor performance, autonomic-nervous-system function, and resistance to neurodegenerative disease. The framework has shaped subsequent fasting-and-brain-health research and is heavily cited in popular literature on fasting's cognitive benefits.

This is the most-cited review of whether fasting and calorie restriction actually trigger autophagy — the cellular self-cleaning process that recycles damaged proteins and organelles. The authors surveyed studies across cell culture, rodent models, and human subjects, looking at autophagy markers such as LC3 lipidation, p62 turnover, ATG7 expression, and mTOR signalling under various fasting and calorie-restriction protocols. Their headline conclusion is that fasting and calorie restriction reliably upregulate autophagy across a wide variety of tissues and organs — liver, muscle, brain, heart, kidney — and that the effect is robust. They also note that autophagy is mechanistically central to the longevity and disease-prevention benefits of caloric restriction: blocking autophagy in animal models attenuates those benefits. The evidence base, however, leans heavily on rodent and cell-culture work; direct measurement of autophagy in living humans is limited because most autophagy markers require tissue biopsy.

This Cell review by Saxton and David Sabatini — Sabatini being one of the original co-discoverers of mTOR — is the most-cited modern synthesis of mTOR signaling biology. The paper traces how mTOR (mechanistic target of rapamycin) integrates four classes of inputs: nutrients (amino acids, especially leucine and arginine), growth factors (insulin, IGF-1), cellular energy state (AMPK senses ATP:AMP), and stress signals. mTOR exists as two complexes: mTORC1, which controls protein synthesis, lipid synthesis, and inhibits autophagy; and mTORC2, which controls cytoskeletal organization and Akt phosphorylation. The review explains how mTORC1 activation drives anabolic programs (cell growth, protein synthesis) while suppressing catabolic programs (autophagy, lipolysis). Conversely, mTORC1 inhibition — by fasting, by rapamycin, by amino acid restriction, or by genetic loss — releases autophagy, increases lipolysis, and engages stress-resistance programs. The paper documents how dysregulated mTOR signaling drives cancer (mTOR is hyperactivated in most tumors), diabetes (mTORC1 contributes to insulin resistance), and aging (mTOR inhibition extends lifespan in every model organism tested). Therapeutic targeting of mTOR is an active drug-development area.

This randomized pilot study asked the cleanest possible head-to-head question for intermittent fasting: when matched for the goal of weight loss, does alternate-day fasting beat ordinary daily caloric restriction? Adults with obesity (BMI ≥30, age 18–55) were randomized to either zero-calorie alternate-day fasting (ADF, n=14) or moderate daily caloric restriction (CR at -400 kcal/day, n=12) for 8 weeks, followed by 24 weeks of unsupervised follow-up. The ADF arm achieved a substantially larger calculated energy deficit (about 376 kcal/day greater than CR), yet the actual weight loss was statistically indistinguishable: ADF -8.2 kg vs CR -7.1 kg over 8 weeks. Body composition, lipids, and insulin sensitivity index showed no significant between-group differences. Safety was strong — no adverse effects, 93 percent completion in the ADF arm. Twenty-four-week unsupervised follow-up showed similar weight regain in both groups, but the ADF arm trended toward more favorable lean-mass preservation. The honest conclusion: ADF is a safe and tolerable alternative to daily restriction with equivalent short-term outcomes, not a superior intervention.

This Cell Metabolism paper from Valter Longo's USC group introduced the fasting-mimicking diet (FMD) — a 5-day periodic dietary protocol designed to deliver fasting's molecular benefits while keeping participants able to consume modest amounts of plant-based food. The paper has two parts. In aged mice, monthly FMD cycles for several months produced multi-system regeneration: hippocampal neurogenesis rose, IGF-1 dropped, PKA activity decreased, NeuroD1 expression increased, and cognitive performance improved on standard mouse cognition tests. In a 38-participant pilot human RCT, three monthly FMD cycles (each 5 days) produced reductions in body weight, body fat, blood pressure, fasting glucose, and IGF-1 without significant adverse events. The paper is foundational because it bridged rodent CR research and practical human protocol design — providing a structured, safe framework for delivering fasting benefits without continuous calorie restriction. Longo subsequently commercialized the protocol as ProLon, a packaged 5-day FMD product. The paper's data quality is solid but the commercial development complicates how it should be cited.

This Canadian government laboratory study tested 52 canned fish products from the 2014 Canadian retail market for bisphenol A (BPA) and three related compounds (BPB, BPE, BPF) using gas chromatography mass spectrometry. The headline finding: BPA was detectable in every one of the 52 products, but at substantially lower levels than a comparable study from five years earlier. The concentration range was 0.96 to 265 nanograms per gram, with an average of 28 ng/g. Three of the four BPA analogues were essentially absent — BPB and BPE were not detected in any product, and BPF appeared in only four samples at low concentrations (1.8 to 5.7 ng/g) — suggesting BPA is still the dominant epoxy resin used in current can liners. The few outliers above 100 ng/g came from a single newly-marketed brand, indicating that brand-level differences in liner formulation drive most of the variation. Industry-wide, the data show measurable downward progress in canned-fish BPA exposure.

This EFSA Scientific Committee statement weighs the cardiovascular and neurodevelopmental benefits of fish consumption against the risks of methylmercury exposure across the European population. It builds on EFSA's 2012 opinion which set the tolerable weekly intake (TWI) for methylmercury at 1.3 µg/kg body weight — meaning a 70 kg adult can safely consume about 91 µg/week. The 2015 statement identifies the dominant European mercury sources by species: tuna (the largest single contributor in adult diets), swordfish, cod, whiting, and pike. Notably, sardines are not on this high-mercury list. The statement acknowledges new epidemiological data (Seychelles cohort) showing that the long-chain omega-3s from fish may counteract some methylmercury toxicity — a benefit-risk tradeoff that favors lower-mercury species like sardines. EFSA's conclusion is risk-tiered: vulnerable groups (pregnant women, children, high-fish consumers up to 6× TWI) should choose lower-mercury species; the general adult population can consume fish at moderate intake without exceeding the TWI.

This Trends in Endocrinology and Metabolism review reframes how the body uses ketone bodies — particularly β-hydroxybutyrate (βOHB) — beyond their traditional role as fuel. Newman and Verdin synthesize evidence that βOHB acts as a signaling molecule through at least two mechanisms. First, βOHB binds at least two cell-surface G-protein-coupled receptors (HCAR2/GPR109A and FFAR3/GPR41), modulating lipolysis, sympathetic tone, and metabolic rate. Second, βOHB directly inhibits class I histone deacetylases (HDACs), which means circulating ketones during fasting or ketogenic diets alter gene expression by changing how DNA is packaged. The review traces implications for caloric restriction, longevity, and aging-related diseases. The paper is a key citation for any claim that ketogenic diets and fasting do work beyond "running on fat instead of carbs" — they trigger gene-expression changes via epigenetic mechanisms with downstream effects on stress resistance, inflammation, and metabolic flexibility. The review is highly cited and has shaped how mechanistic ketosis research is framed.

This Cell Metabolism paper combined a large NHANES-based human cohort (2,253 adults followed over 18 years) with mouse experiments to ask whether high protein intake — especially animal protein — drives cancer and mortality risk via IGF-1 and growth-hormone signalling. The headline finding is age-dependent. In adults aged 50–65, those reporting high protein intake (≥20 percent of calories from protein) had a 75 percent higher overall mortality and a fourfold higher cancer death risk over the next 18 years compared to low-protein eaters (under 10 percent of calories). The effect was largely abolished when the protein came from plant sources rather than animal sources. After age 65, the relationship reversed: high protein became protective for cancer and overall mortality — though high protein at any age was associated with a fivefold increase in diabetes mortality. Mouse experiments supported the mechanism: high-protein diets accelerated tumour growth and elevated IGF-1, while protein restriction did the opposite. The interpretation is that protein's relationship with longevity is not monotonic; it depends on age, on the protein source, and on what's being optimized for.

Philip Calder is the leading authority on omega-3 fatty acids and inflammation, and this 2013 BJCP review is his most cited synthesis. The paper traces the multiple mechanisms by which EPA and DHA modulate inflammatory responses: incorporation into cell-membrane phospholipids alters which substrates are available for eicosanoid synthesis (prostaglandins, leukotrienes); direct inhibition of leukocyte chemotaxis, adhesion-molecule expression, and T-cell reactivity; reduced inflammatory cytokine production (TNF, IL-1β, IL-6); disruption of lipid rafts that anchor TLR4 signaling; and generation of pro-resolution lipid mediators (resolvins, protectins) that actively terminate inflammation rather than just dampen it. The paper distinguishes "nutrition-dose" effects (typical 1–2 g/day EPA+DHA from regular fish intake, modest anti-inflammatory shifts) from "pharmacology-dose" effects (3–4 g/day or higher, with measurable effects on rheumatoid arthritis and other clinical inflammatory conditions). The clinical evidence base is strongest for rheumatoid arthritis; weaker and inconsistent for inflammatory bowel disease and asthma.

This study tested 17 different brands of canned sardines, sourced from six countries and bought at retail in eastern Kentucky, for the four most concerning heavy metals in fish: arsenic, cadmium, lead, and mercury. Each brand was analyzed as a composite of 3 to 4 fish using standard atomic-absorption laboratory methods. The headline finding for sardines was clear: mercury was below the 0.09 microgram-per-gram detection limit in every sample tested. That is well under the 1.0 microgram-per-gram FDA action level for predatory fish like tuna and swordfish, and roughly a tenth of the typical canned-tuna averages reported in FDA surveillance data. Arsenic was the highest of the four metals on average (1.06 µg/g), with the highest values appearing in samples from Norway and Thailand; cadmium was highest in Moroccan brands; lead was highest in Canadian brands. The study supports the narrow but important claim that commercial canned sardines, across multiple sourcing countries, are a low-mercury fish.

This meta-analysis pooled 11 randomized controlled trials with 618 total participants to ask whether omega-3 fish oil supplements improve insulin sensitivity in adults. Across all studies and measurement methods, the answer was essentially no. The overall standardized effect size was 0.08 (95% confidence interval -0.11 to 0.28) — statistically indistinguishable from zero. One subgroup analysis was the exception. When researchers used HOMA-IR — a calculation from fasting glucose and insulin — omega-3 supplementation showed a small but statistically significant improvement (effect size 0.30, CI 0.03 to 0.58). On more direct measures of insulin sensitivity, including the euglycemic clamp, the effect was absent. The honest read: at the doses and durations studied, typically 1 to 4 grams of EPA plus DHA per day for weeks to months, omega-3 supplements do not reliably improve insulin sensitivity in adults — though a small HOMA-IR signal exists.

Before this paper, the dominant view was that the brain was metabolically privileged — protected from the autophagy-inducing effects of food restriction so that neurons could maintain function during starvation. Alirezaei and colleagues at the Scripps Research Institute overturned that assumption. Using mice fasted for 24 to 48 hours, they directly measured autophagy markers in cortical neurons and Purkinje cells (the large output neurons of the cerebellum). They found dramatic upregulation: increased numbers of autophagosomes, altered autophagosome characteristics, and decreased neuronal mTOR activity (measured via reduced phosphorylation of S6 ribosomal protein). Transmission electron microscopy directly visualized the autophagosome accumulation. The paper's interpretation: short-term fasting is a simple, non-pharmacological intervention that produces measurable brain autophagy responses. The authors speculated that periodic fasting could be a low-cost approach to engaging neural autophagy as a therapeutic mechanism for protein-aggregation neurodegenerative diseases. The paper has been cited heavily in subsequent fasting-and-brain-health literature and in popular science writing on fasting's neurological benefits.

This 12-week randomized trial compared a carbohydrate-restricted diet (12 percent carb / 59 percent fat / 28 percent protein) with a low-fat diet (56 percent carb / 24 percent fat / 20 percent protein) in 40 adults with atherogenic dyslipidemia — the metabolic-syndrome phenotype defined by high triglycerides, low HDL, central adiposity, and insulin resistance. Both diets were calorie-restricted to similar levels. Both produced improvements, but the carbohydrate-restricted arm consistently outperformed the low-fat arm across nearly every endpoint that defines metabolic syndrome. Glucose dropped 12 percent in the carb-restricted group; insulin fell 50 percent; insulin sensitivity improved 55 percent; body weight dropped 10 percent; adiposity dropped 14 percent. The lipid panel was the most striking divergence: triglycerides fell 51 percent on carb restriction (versus a smaller drop on low-fat), HDL rose 13 percent (versus no change), and the total-cholesterol-to-HDL ratio improved 14 percent more on carb restriction. The paper's interpretation is that the metabolic syndrome is fundamentally a carbohydrate-intolerance phenotype, and that restricting carbs addresses the upstream driver more directly than restricting fat does.